Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin

Shahideh Amini, Kheirollah Gholami, Hooman Bakhshandeh and Bahram Fariborz Farsad

*Clinical Pharmacy Department, Pharmacy School, Tehran University of Medical Sciences, Tehran, Iran. †Faculty of Pharmacy and Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran. ‡Cardiac Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Tehran University of Medical Sciences, Tehran, Iran. †Rajaie Cardiovascular Medical and Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Atrial fibrillation (AF) is associated with inflammatory and hypercoagulability state. Previous studies evaluated the safety and efficacy of dabigatran and warfarin in prevention of thromboembolic complications. This study was intended to assess the influence of these drugs on hemostatic and inflammatory markers among patient underwent pulmonary vein ablation. A total of 100 patients with AF who underwent catheter ablation were randomized to treatment with dabigatran (D) 110 mg twice daily or warfarin (W) adjusted to an international normalized ratio (INR) of 2.0 to 3.0 for 3 months after ablation procedure. C-reactive protein (CRP), D-dimer, prothrombin fragment F1 + 2 (F1 + 2), were measured at baseline before ablation procedures, after 30 days and after 90 days of treatment. After 3 months, the D-dimer was 164.9 ± 48.9 in Dabigatran and 197.2 ± 58.6 in warfarin group, F1 + 2 was 0.4 ± 0.2 in dabigatran and 0.8 ± 0.2 in warfarin group and CRP level was 1.8 ± 1.6 in Dabigatran and 5.1 ± 5 in warfarin group. (All p-values < 0.05)

The results showed that treatment with dabigatran made greater changes in the serum level of CRP, D-dimer, F1 + 2. The pattern of changes in serum CRP levels D-dimer, F1 + 2 is much faster and with a greater slope in the dabigatran group.

Keywords: Anticoagulant therapy; Inflammatory; Dabigatran; Warfarin.

Introduction

Atrial fibrillation (AF) remains the most common cardiac arrhythmia which is associated with increased morbidity and mortality. Thromboembolic events are the most prevalent complication of AF (1, 2).

The underlying patho-physiologies of AF are multifactorial. Recent studies have indicated that atrial fibrillation; is a heterogeneous disease with numerous interacting mechanisms involved in the genesis, maintenance and persistence of it (3, 4).

Current evidences have suggested that coagulation activation, abnormal inflammation and endothelial dysfunction play an important role in the pathogenesis of AF (5, 6). Elevation of inflammatory markers such as interleukin-6 and C-reactive protein were seen in AF patients.
Indeed hypercoagulable or prothrombotic states may be detected in AF patients and there is a significant association between inflammatory markers and thrombogenesis, in which elevation of inflammatory markers leads to an increase in the risk of vascular events (8-10). Despite oral anticoagulation (OAC), AF patients continue to suffer from thromboembolic stroke and in many cases the occurrence of cerebral infarction is silent (11). Until recent years warfarin has been the only effective oral anticoagulant therapy for the prophylaxis of stroke in AF patients. Nevertheless, the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study showed superiority of dabigatran over warfarin in the prevention of stroke and systemic embolism (12).

While dabigatran has a place in the therapeutic prevention stroke and systemic embolism associated with AF, there is no study that has compared the effect of this drug on inflammatory and hemostatic markers with warfarin, so we performed a randomized trial to compare the effect of dabigatran at doses of 110 mg twice daily with warfarin adjusted to an international normalized ratio (INR) of 2.0 to 3.0 in AF patients post single circumferential pulmonary vein ablation on markers of thrombin generation (prothrombin fragment F1 + 2 (F1 + 2)), fibrin turnover (fibrin D-dimer) and inflammation (c-reactive protein, CRP).

**Experimental**

**Patients**

We performed a randomized controlled trial of patients undergoing AF ablation for drug-refractory, symptomatic AF between January 2010 and July 2011 at Rajaie Cardiovascular Medical and Research center in Tehran, a tertiary health care providing hospital. The study protocol was approved by the local institutional review board and informed written consent was obtained from all the participants after registration in the study.

Patients with drug-refractory, symptomatic AF who had indications for ablation included in this study. Patients were excluded in the presence of a severe heart-valve disorder, stroke within 14 days or severe stroke within 6 months before screening, a condition that increased the risk of hemorrhage, a creatinine clearance of less than 30 mL per minute, an active liver disease, and pregnancy at the time of the ablation procedure. Registration was performed by an electrophysiologist who was a member of scientific board of our institute.

Randomization, study groups and endpoints

After providing AF ablation procedures and participants registration, 100 patients were randomly assigned to receive 110 mg dabigatran (Pradaxa®, BoehringerIngelheim) twice daily, or to receive warfarin adjusted to an international normalized ratio (INR) of 2.0 to 3.0, for at least 90 days after the AF ablation procedure.

Randomization was performed using the balanced block method (block of four). Randomization concealment was applied using the sealed envelope method. The process of randomization and concealment was carried out by one of the authors who did not participate in the patients’ enrollment, treatment, follow up and data collection.

Primary endpoints of the study were to determine and compare the changes in blood levels of F1+2, D-dimer and CRP between two study groups. Comparison of the thrombotic complications and safety profile was the secondary endpoints of the study.

**Blood sampling and assays**

Venous blood was drawn with a 21-22 gauge needle. Blood was collected into vacutainer tubes containing citrate 3.8%. The blood was centrifuged within at 2000 g for 20 min and stored at -70 until analysis. All laboratory technicians who were involved in blood sampling, analyzing and reporting the results had been masked to the randomized status and treatment of the study participants. The INR, PT, aPTT, F1 + 2, D-dimer and CRP were measured at baseline before ablation procedures, after 30 days (in the first visit of patients after ablation in our center) and after 90 days of treatment (minimum anti-coagulation therapy after AF ablation (13)). In the warfarin group, Time in Therapeutic range (TTR) was calculated by the Rosendaal method (14).

The APTT and PTT were analyzed by C.K
PREST®and NEOPLASTINE ®cl respectively. F1 + 2 and D-dimer were analyzed with commercial immunoassays (Enzygnost®, Dade Behring for F1+2 and VIDAS® for D-dimer). Levels of CRP were measured with CRP-Latex Immunoturbidometric Assay (CRP-LIA). All analyses were performed at the laboratory in our institute.

**Statistical analysis**

Data were described as mean ± standard deviation for interval and count (percent) for categorical variables. One sample Kolmogorov-Smirnov test was applied to find the fitness of interval variables with normal distribution. Baseline data were compared between the two study groups with Student’s t test (for interval variables) and Pearson’s chi square or Fisher’s exact tests (for categorical variables). Repeated measure analysis of variance (ANOVA) models were applied to investigate the changes of study outcomes through the time and the associations with the types of treatment (study groups) and also the interactions. Bonferroni post-hoc test was applied for pair wise comparisons. P-value < 0.05 was considered as statistically significant. Intention to treat (ITT) approach was considered for data analysis.

Multivariate analysis was performed by using generalized estimating equations (GEE) method. In these models, the adjusted associations between blood levels of CRP in the baseline, first month and third month after treatment and the type of treatment (dabigatran or warfarin) were investigated.

IBM® SPSS® Statistics 19 for Windows® (IBM Corporation, New York, USA, 2010) was used for statistical analysis.

**Results**

**Study participants and their baseline characteristics**

From June 2011 to July 2012, a total number of 112 patients were assessed for the study inclusion criteria. One hundred people who met the criteria were randomly assigned to the dabigatran or the warfarin group, 50 in each group. The mean age of the participants was 58 ± 11.7 years and the female/male ratio was 52/48. The patients’ characteristics are summarized in Table 1. No significant differences were observed between the study groups.

All the participants received the assigned treatment and were followed until the three months after. No withdrawal or loss to follow up occurred after treatment (Figure 1). The INR level was in therapeutic range in all the patients. The mean percent time in therapeutic INR range (TTR) in this group at the third month after treatment was 52% ± 6.8%.

**Comparison of outcomes and safety between the study groups**

**D-dimer**

Results are presented in Table 2. In addition, changes in plasma levels of D-dimer in three months of follow-up and the comparisons between the two study groups are shown in Figure 2. These findings showed that the plasma levels of D-dimer after 3 months were significantly different between the two groups (164.9 ± 48.9 in dabigatran and 197.2 ± 58.6 in the warfarin group, p-value = 0.003).

Repeated measure ANOVA model revealed that the interaction between treatment and study groups was significant (p-value = 0.013). It means that the effect of dabigatran to reduce the blood level of D-dimer was greater than warfarin. Between the first and third months after treatment, the rate of decrease was faster and the final blood levels of D-dimer were the less in dabigatran group (Figure 2).

**Prothrombin fragment F1 + 2**

Table 2 shows that the difference between dabigatran and warfarin groups in the blood levels of F1 + 2 was significant (0.4 ± 0.2 in dabigatran and 0.8±0.2 in warfarin group, p-value < 0.001).

Statistical analysis confirmed that the interaction between type of treatment and F1+2 was significant (p-value = 0.002). Similar to D-dimer, reduction in blood level of F1+2 was significantly faster in treatment with dabigatran rather than warfarin after the first month (Figure 3).

**C-reactive protein**

After 3 months, the CRP level significantly decreased in the dabigatran group (1.8 ± 1.6 in
was observed that significant association existed between the type of treatment and changes in CRP levels ($\beta = -8.21 \pm 2.57$, $p$-value = 0.001). It means that dabigatran caused more reduction in blood CRP levels compared to warfarin. In addition, diabetes showed significant associations after adjustment (Table 3). By other word, among different predictors, only diabetes showed a significant relationship with higher serum CRP levels. Other important factors, such as affliction to heart failure, chronic kidney disease and hypertension didn’t show any statistically significant associations with CRP levels.

**Safety and adverse drug reactions**

No bleeding and any other adverse effects were observed.

---

**Table 1. Baseline characteristics in the two study groups.**

|                                | Dabigatran (n = 50) | Warfarin (n = 50) | p-value |
|--------------------------------|----------------------|-------------------|---------|
| Age years                      | 56 ± 14.4            | 60 ± 8.2          | 0.442   |
| Age ≥ 65 years                 | 18 (36%)             | 11 (22%)          | 0.123   |
| Sex (F/M)                      | 25/25                | 27/23             | 0.689   |
| Body Mass Index                | 26.4 ± 2.9           | 28.7 ± 4.1        | 0.161   |
| AF Duration months             | 25.6 ± 25.5          | 25.7 ± 16.9       | 0.998   |
| Heart Failure (n = 11)         | 6 (12%)              | 5 (10%)           | 0.749   |
| Hypertension (n = 51)          | 28 (56%)             | 23 (46%)          | 0.317   |
| Diabetes (n = 30)              | 17 (34%)             | 13 (26%)          | 0.180   |
| Coronary Artery Disease (n = 18)| 14%                  | 11 (22%)          | 0.298   |
| Chronic renal insufficiency (n = 6)| 10%              | 1 (2%)            | 0.204   |
| Alcohol Drinking (n = 13)      | 10%                  | 7 (14%)           | 0.538   |
| Medical Treatments             |                      |                   |         |
| Aspirin (n = 22)               | 10 (20%)             | 12 (24%)          | 0.273   |
| ACE Inhibitors (n = 35)        | 18 (36%)             | 17 (34%)          | 0.834   |
| Statins (n = 33)               | 19 (38%)             | 22 (44%)          | 0.542   |
| Beta Blockers (n = 31)         | 12 (24%)             | 19 (38%)          | 0.130   |
| Calcium Channel Blockers (n = 23)| 20%              | 13 (26%)          | 0.476   |
| CHADS2-VASC score              | 1.55 ± 1.44          | 2 ± 0.87          | 0.177   |
| CHADS2-VASC score              | 0                    | 18 (36%)          |         |
| ≥2                             | 5 (10%)              | 11 (22%)          |         |
| HAS-BLED score                 | 0.69 ± 0.2           | 0.73 ± 0.24       | 0.142   |
| HAS-BLED score                 | 0                    | 27 (54%)          |         |
| ≥2                             | 5 (10%)              | 17 (34%)          |         |

**Multivariate analysis**

Multivariate analysis was performed by GEE model and the result is presented in Table 3. After adjustment for several determinants, dabigatran and 5.1 ± 5.0 in the warfarin group, $p$-value < 0.001). Repeated measure ANOVA model suggested that there was a significant interaction between treatment and study groups ($p$-value = 0.041). It means that similar to D-dimer, the pattern of changes in serum CRP levels is much faster and with a greater slope in the dabigatran group. By other words, in spite of the greater levels of serum CRP in the dabigatran group at the baseline, the drug made a significant decrease in the patients’ serum CRP (Figure 4).
Figure 1. Flow Diagram of the Study Participants.

- Assessed for eligibility (n=112)
- Excluded (n=12)
  - Not meeting inclusion criteria (n=12)
- Randomized (n=100)
  - Allocated to Dabigatran (n=50)
    - Received Dabigatran (n=50)
  - Allocated to Warfarin (n=50)
    - Received Warfarin (n=50)
  - Lost to follow-up (n=0)
  - Discontinued intervention (n=0)
- Analysed (n=50)
  - Lost to follow-up (n=0)
  - Discontinued intervention (n=0)
  - Allocated to Dabigatran (n=50)
  - Received Dabigatran (n=50)
  - Allocated to Warfarin (n=50)
  - Received Warfarin (n=50)

Figure 2. Comparison of changes in blood D-dimer levels between two groups of patients.

Figure 3. Comparison of changes in Prothrombine Fragment F1+2 levels between two groups of patients.
The results of this study show that prescription of dabigatran in patients with AF who undergo catheter ablation leads to the decrease in D-dimer, CRP and F1+2 in a period of three months after ablation and this decrease is higher in comparison to the group who have received warfarin. Although the pathophysiology of atrial fibrillation and the mechanism that causes increase in the risk of thromboembolic events in this disease has not been identified correctly, findings show that inflammatory processes have an important role in the onset of the disease and its continuance and this disease is associated with a hypercoagulable and prothrombotic state (3, 15). Yet it is not clearly obvious whether inflammation is the outcome of the disease or the etiology of the disease (16). Some studies believe that early recurrence of AF after ablation may be due to inflammatory processes. In a study recently performed, it has been proven that the level of interleukin 6 and CRP are relatively associated with the recurrence rate of AF after ablation (17, 18).

In addition, there is a mutual association between inflammatory processes and the hemostatic system. Inflammation leads to elevation of coagulation factors and decrease of fibrinolytic pathways. These changes result in a hypercoagulable and thrombotic state. A higher level of D-dimer and VWF is associated with an increase in the prevalence of stroke (19, 20).

In addition, there is a mutual association between inflammatory processes and the hemostatic system. Inflammation leads to elevation of coagulation factors and decrease of fibrinolytic pathways. These changes result in a hypercoagulable and thrombotic state. A higher level of D-dimer and VWF is associated with an increase in the prevalence of stroke (19, 20).

The level of hemostatic markers may predict the course of the disease (21).

In addition to the prognostic role of hemo-

| Table 2. Comparison of outcomes between the study groups. |
|----------------------------------------------------------|
| **Treatment Group** | **Dabigatran** (n = 50) | **Warfarin** (n = 50) | **P value** |
| D-dimer | | | |
| Baseline | 333.6 ± 81.4^{†,‡} | 303.9 ± 118.1^{†,§} | 0.147 |
| Month 1 | 287.9 ± 91.7^{†,‡} | 262.2 ± 69.3^{†,§} | 0.118 |
| Month 3 | 164.9 ± 48.9^{‡,§} | 197.2 ± 58.6^{‡,§} | 0.003 |
| **Time-Treatment Interaction** | | | 0.013 |
| Prothrombin fragment F1+2 | | | |
| Baseline | 1.8 ± 0.6^{†,‡} | 1.6 ± 0.8^{†,§} | 0.161 |
| Month 1 | 1.5 ± 0.8^{†,‡} | 1.4 ± 0.6^{†,§} | 0.450 |
| Month 3 | 0.4 ± 0.2^{‡,§} | 0.8 ± 0.2^{‡,§} | <0.001 |
| **Time-Treatment Interaction** | | | 0.002 |
| C Reactive Protein | | | |
| Baseline | 11.3 ± 12.2 | 7.4 ± 10.7 | 0.100 |
| Month 1 | 5.9 ± 4.9^{†} | 6.5 ± 7.5 | 0.625 |
| Month 3 | 1.8±1.6^{†} | 5.1± 5.0 | <0.001 |
| **Time-Treatment Interaction** | | | 0.041 |

* Assessed by repeated measure ANOVA models.
†, ‡, §: Statistically significant results in pairwise comparisons within groups, using Bonferroni post-hoc test.

**Discussion**

The results of this study show that prescription of dabigatran in patients with AF who undergo catheter ablation leads to the decrease in D-dimer, CRP and F1+2 in a period of three months after ablation and this decrease is higher in comparison to the group who have received warfarin. Although the pathophysiology of atrial fibrillation and the mechanism that causes
static markers, the impacts of drugs have also been evaluated. Therapeutic doses of warfarin and an INR in the range of 2-3 may decrease the level of markers, while aspirin and low doses of warfarin may have no effect on hemostatic markers (22, 23).

On the other hand, other studies have proved that warfarin has no effect on platelet markers, but it decreases the level of coagulation markers. This finding has been clinically approved that activation of the coagulation cascade has a more determinant role in comparison to the increase in platelet activity and also warfarin is more efficient than aspirin in the prevention of thrombotic events (6).

Not only hypercoagulable states can occur after inflammatory processes, but also the coagulation system may affect the inflammatory process significantly.

Among these coagulable factors, thrombin, which is considered as an important component and a pivotal central enzyme in the hemostatic system, can increase the expression of specific cell receptors on mononuclear cells or endothelial cells and consequently induced inflammatory cytokine and growth factors production. Thrombin by means of binding to protease-activated receptors (PARs) may stimulate the secretion of proinflammatory mediators and several growth factors (24, 25).

Direct thrombin inhibitor as a therapeutic agent, which may affect thrombin as the last target of the coagulation pathway, may have an important role on the coagulation pathway and probably the inflammatory process. In animal studies, thrombin has increased inflammation and thrombin inhibitor medications were able to decrease the thrombin-induced inflammation (26).

In the animal model, it was determined that dabigatran may decrease fibrosis and inflammation and may also decrease lung injury in the interstitial lung disease model (27).

In the present study, dabigatran has been able to decrease inflammatory and also hemostatic markers, while this decrease was less in the warfarin group. In the literature, no anti-inflammatory effect has been detected for warfarin and only hemostatic factors has been influenced by the drug treatment (24, 28, 29).

In clinical studies and trials that compared dabigatran and warfarin, safety and bleeding complications and also the incidence of thrombotic events such as the incidence of stroke have been compared (12).

No comparison has been made between the impacts of these drugs on these markers. Besides, the clinical effect of these changes has not been evaluated till now. Since there is an association between the incidence of disease attacks and the inflammatory processes, the effect of dabigatran on these inflammatory markers may
be of importance (30).

It has been observed that in addition to the high risk of accidents such as stroke AF patients face, these patients in spite of anti coagulant therapy are also at risk for microthrombotic events such as dementia. Suppression of D-dimer may decrease the probability of dementia in these patients (31-33).

The effect of dabigatran on thrombin and consequently the decrease of inflammatory markers which have been detected in this study and also the higher decrease of D-dimer levels in comparison to warfarin may enlighten researchers regarding the positive results of this drug on lowering microthrombotic events.

The small sample size and not evaluating the recurrence rate of AF in the patients were the limitations of this study. Therefore, we suggest performing studies in the future to evaluate the clinical impact of change in marker levels.

Acknowledgment

This article was a report of an academic project in Tehran University of Medical Sciences and drugs were provided by BoehringerIngelheim Company. The authors declare that there was not any other conflict of interest in the study.

References

(1) Ahmad Y and Lip GY. Stroke prevention in Atrial Fibrillation: concepts and controversies. Curr. Cardiol. Rev. (2012) In press.
(2) Desai NR and Giugliano RP. Can we predict outcomes in atrial fibrillation? Cll. Cardiol. Suppl. (2012) 35: 10-4.
(3) Issac TT, Dokainish H and Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: systematic review of the published data. J. Am. Coll. Cardiol. (2007) 50: 2021-28.
(4) Friedrichs K, Kline A and Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends. Mol. Med. (2011) 17: 556-63.
(5) Kouriouros A, Kiotsekoglou A, Jahangiri M and Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am. Heart J. (2009) 157: 243-52.
(6) Watson T, Shantsila E and Lip G. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. The Lancet. (2009) 10: 152-64.
(7) Roldan V, Marin F, Blann AD, Garcia A, Marco P, Sogorb F and Lip GY. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur. Heart J. (2003)24: 1373-80.
(8) Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A and Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. (2001) 104: 2886-91.
(9) Aviles RJ, Martin DO, Apperson-Hansen C, Houghaling PL, Rautaharju P, Kromal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS and Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation. (2003) 108: 3006-10.
(10) Engelmann MD and Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur. Heart J. (2005) 26: 2083-92.
(11) Ezekowitz MD, James KE, Nazarian SM, Davenport J, Broderick JP, Gupta SR, Thadani V, Meyer ML and Bridgers SL. Silent brain infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation. (1995) 92: 2178-82.
(12) Cotmolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Thmeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Dienier HC, Joyner CD and Wallentin L. RE-LY Steering Committee and Investigators. dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. (2009) 361: 1139-51.
(13) Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM.2011ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. (2011) 57:1330-7.
(14) Rosendaal FR, Canneel SC, van der Meer FJ and Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. (1993) 69: 236-9.
(15) Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, Toffler GH, Selhub J, Jacques PF, Wolf PA, Magnani JW, Ellinor PT, Wang Tj, Levy D, Vasan RS and Benjamin EJ. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. (2010) 121: 200-7.
(16) Marcus GM, Smith LM, Ordovas K, Scheinman MM, Kim AM, Badhwar N, Lee RJ, Tseng ZH, Lee BK and Olgin JE. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. (2010) 7: 149-54.
(17) Lin YJ, Tsao HM, Chang SL, Lo LW, Tuan TC, Hu YF, Udyavar AR, Tsai WC, Chang CJ, Tai CT, Lee PC, Suenari K, Huang SY, Nguyen HT and Chen SA. Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation. *Am. J. Cardiol.* (2010) 105: 495-501.

(18) Deftereos S, Giannopoulos G, Kossyvakis C, Efremidis M, Panagopoulou V, Kaoukis A, Raisakis K, Bouras G, Angelidis C, Theodorakis A, Driva M, Doudoumis K, Pyrgakis V and Stefanadis C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. *J. Am. Coll. Cardiol.* (2012) 60: 1790-6.

(19) Maas MB and Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. *Biomark. Med.* (2009) 3: 363-83.

(20) Sadanaga T, Sadanaga M and Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. *J. Am. Coll. Cardiol.* (2010) 55: 2225-31.

(21) Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM and Folsom AR. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. *Int. J. Cardiol.* (2012) 155: 217-22.

(22) Mitsch R, Siemens HJ, Garbe M, Wagner T, Sheikhzadeh A and Diederich KW. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. *Thromb. Haemost.* (1996) 75: 219-23.

(23) Li-Saw-Hee FL, Blann AD and YH, Lip G. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy. Stroke. (2000) 31: 828-33.

(24) Coughlin SR. Thrombin signaling and protease-activated receptors. *Nature* (2000) 407: 258-64.

(25) Mann KG. Thrombin formation. *Chest.* (2003) 124: 4-108.

(26) Vergnolle N, Hollenberg MD, and Wallace JL. Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1). *Br. J. Pharmacol.* (1999) 126: 1262-68.

(27) Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, Akter T, van Ryn J and Silver RM. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatranexilale in a murine model of interstitial lung disease. *Arthritis Rheum.* (2011) 63: 1416-25.

(28) MacCallum PK, Rudnicka AR, Rumley A, Meade TW and Lowe GD. Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. *Br. J. Haematol.* (2004) 127: 448-50.

(29) Lip GY, Lowe GDO, Rumley A and Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. *Br. Heart J.* (1995) 73: 527-33.

(30) Palagummi P, Sultzman H and Ezekowitz M: Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties. *Am. Heart J.* Suppl. (2005) 149: s32-s5.

(31) Barber M, Tait RC, Scott J, Rumley A, Lowe GD and Stott DJ. Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. *J. Thromb. Haemost.* (2004) 2: 1873-78.

(32) Knecht S, Oelschläger C, Duning T, Lohmann H, Albers J, Stelling C, Heindel W, Breithardt G, Berger K, Ringelstein EB, Kirchhof P and Wersching H. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. *Eur. Heart J.* (2008) 29: 2125-32.

(33) Stott DJ, Robertson M, Rumley A, Welsh P, Sattar N, Packard CJ, Shepherd J, Trompet S, Westendorp RG, de Craen AJ, Jukema JW, Buckley B, Ford I and Lowe GD. Activation of hemostasis and decline in cognitive function in older people. *Arterioscler. Thromb. Vasc. Biol.* (2010) 30: 605-11.

---

This article is available online at http://www.ijpr.ir